ABSTRACT Background: Autism is a complex neurodevelopmental disorder that is increasingly being recognized as a public health issue. Recent evidence has emerged that children with autism may have altered folate or methionine metabolism, which suggests the folate-methionine cycle may play a key role in the etiology of autism. Objective: The objective was to conduct a systematic review to examine the evidence for the involvement of alterations in folatemethionine metabolism in the etiology of autism. Design: A systematic literature review was conducted of studies reporting data for metabolites, interventions, or genes of the folate-methionine pathway in autism. Eighteen studies met the inclusion criteria, 17 of which provided data on metabolites, 5 on interventions, and 6 on genes and their related polymorphisms. Results: The findings of the review were conflicting. The variance in results can be attributed to heterogeneity between subjects with autism, sampling issues, and the wide range of analytic techniques used. Most genetic studies were inadequately powered to provide more than an indication of likely genetic relations. Conclusions: The review concluded that further research is required with appropriately standardized and adequately powered study designs before any definitive conclusions can be made about the role for a dysfunctional folate-methionine pathway in the etiology of autism. There is also a need to determine whether functional benefits occur when correcting apparent deficits in folate-methionine metabolism in children with autism.
INTRODUCTION
Autism spectrum disorders (ASDs) are increasingly recognized as a public health issue. ASDs are characterized by impairments in reciprocal social interaction and communication and restricted interests as well as repetitive stereotypic behaviors (1) . The term autism spectrum disorder encompasses autistic disorder, Asperger disorder, and pervasive development disordersnot otherwise specified. Over the past 20 y, the number of diagnosed cases has significantly increased. This has been partly attributed to broadening of the diagnostic criteria and increased community awareness (2) .
Recent well-designed studies using whole-genome scanning methods indicate a key role for genetic factors in the etiology of autism (3) (4) (5) . These studies have shown that multiple genes contribute to the wide range of symptoms observed in autism (6) . A common aberration is not consistently seen in all autism cases, which suggests that it is a cluster of disorders with each having a distinct pathophysiology. In addition, environmental factors, including heavy metal toxicity (7) (8) (9) , subclinical viral infections (10) , and gastrointestinal pathology (reviewed in references 11 and 12), have also been identified as contributing to autism.
Folate and methionine metabolism and autism
A dysfunctional folate-methionine pathway has been identified in many individuals with autism. This pathway is crucial for DNA synthesis (13) , DNA methylation (14) , and cellular redox balance (15) . As shown in Figure 1 , methionine, an essential amino acid, is converted to S-adenosyl-methionine (SAM), the body's main methyl group donor, which is converted to S-adenosylhomocysteine (SAH) during methylation reactions. Thus, plasma SAM:SAH indicates methylation status. SAH is later hydrolyzed to homocysteine in a reversible reaction releasing adenosine.
Homocysteine formed from methylation reactions is metabolized by 1 of 2 pathways. The first is the trans-sulfuration pathway, which involves the irreversible conversion of homocysteine to cysteine through cystathionine. Cysteine is the ratelimiting amino acid for the synthesis of glutathione, which plays a key role in detoxification processes (16) . Total glutathione: oxidized glutathione in plasma is an indicator for oxidative stress (17) . The second pathway involves the remethylation of homocysteine to methionine, which is carried out by methionine synthase (MS) in most tissues.
A shown in Figure 2 , the methyl group for MS is donated by 5-methyltetrahydrofolate (5-MTHF), which is converted to tetrahydrofolate (THF). THF is methylated to become 5,10-methylene tetrahydrofolate (5,10-MTHF) either by serine hydroxyl-methyltransferase or a series of 3 reactions catalyzed by methyltetrahydrofolate dehydrogenase (MTHFD-1).
Most 5,10-MTHF is metabolized to 5-MTHF, the only form of folate used in the central nervous system (CNS) and the main form of folate in the blood, by methylene tetrahydrofolate reductase (MTHFR). The remaining 5,10-MTHF is converted to dihydrofolate (DHF) by thymidine synthase in the synthesis of thymidylate, which is required for DNA replication and may be converted back to THF by dihydrofolate reductase (DHFR).
Significant cytogenetic alterations in both lymphocytes and/or buccal cells have been found in other neurologic conditions, including Down syndrome, Parkinson disease, Alzheimer disease, and schizophrenia (18) (19) (20) (21) . Although it is plausible that folate deficiency increases chromosomal instability (22) , there is currently no direct evidence that chromosomal DNA damage is the cause of neurodegenerative disease. Other plausible mechanisms for a role of folate deficiency in neurodegenerative diseases include impaired mitochondrial function due to mitochondrial DNA deletions, reduced availability of methyl groups from folate for neurotransmitter synthesis, and reduced proliferative potential of regenerative cells in critical regions of the brain caused by diminished nucleotide synthesis (23, 24) .
Folate transport into the CNS
Folate transport through the choroid plexus is mainly mediated by a family of folate receptor (FR) proteins, and the reduced folate carrier 1 (RFC-1) ( Figure 3 ) FR proteins located on the plasma side of the choroid plexus bind and transfer folate via endocytosis into the intracellular compartment where it is concentrated. The RFC-1 is located on the cerebrospinal fluid (CSF) side of the choroid plexus, where it facilitates transport of the concentrated folate into the CSF. Defective folate transport into the CNS has been linked with cerebral folate deficiency (CFD), a condition associated with developmental delays (with or without autistic features), providing plausibility for involvement of the folate-methionine pathway in autism (reviewed in reference 25) . This article systematically reviews the evidence for a role of the folate-methionine pathway in the etiology of autism, because, to our knowledge, no such article has been published to date.
METHODS
A systematic literature review was conducted to identify folate-methionine pathway studies in autism, including metabolite concentrations in blood, interventions directed at normalizing a dysfunctional pathway and genes, and related polymorphisms of the pathway. The search used the following electronic databases (all databases were accessed through our institution's subscription, with the exception of The Cochrane Library): Embase, Medline, Cinahl, Scopus, Web of Science, International Pharmaceutical Abstracts, and the Cochrane database (available from http://www.thecochranelibrary.com). The reference lists for all obtained studies were hand-searched for additional studies.
The criteria for study inclusion were as follows: 1) studies in children with autistic disorder as described in the Diagnostic and Statistical Manual of Mental Disorders: Revised Text (DSM-IV-R) (1) or diagnosed by using a standard diagnostic instrument, eg, the Childhood Autism Rating Scale (CARS) (26); and 2) studies including data for receptors, carriers, metabolites, cofactors or genes of the folate-methionine pathway, and/or 3) interventions using metabolites or cofactors of the folate-methionine pathway. Only full-text English-language articles published between 1978 and October 2008 were included.
All potential studies identified were independently evaluated for inclusion by 2 primary reviewers (PM and MA). The primary reviewers were not blinded to the authors, institutions or source of publication at any time during the selection process. Disagreements about the inclusion/exclusion of studies were discussed and consensus achieved. Provision was made for a third reviewer if consensus was unattainable but did not prove necessary. A level of evidence was assigned to each study by using the Australian FIGURE 2. Folate cycle. THF, tetrahydrofolate; 5-methyl-THF, 5-methyltetrahydrofolate; 5,10-MTHF, 5,10-methylene-tetrahydrofolate; DHF, dihydrofolate; 10-formyl-THF, 10-formyl-tetrahydrofolate; 5,10-methenyl-THF, 5,10-methenyl-tetrahydrofolate; dUMP, deoxy-uracil-monophosphate; dTMP, deoxy-thymidine-monophosphate; cSHMT, cyclo-serine-hydroxy methyl transferase; MTHFR, 5,10-methylene tetrahydrofolate reductase; MS, methionine synthase; MSR, methionine synthase reductase; MTHFD1, 5,10-methylenetetrahydrofolate dehydrogenase/5,10-methenyl-tetrahydrofolate cyclohydrolase/10-formyl-tetrahydrofolate synthetase; DHFR, dihydrofolate reductase; TS, thymidine synthase; B6, vitamin B-6; Vit. B12, vitamin B-12. National Health and Medical Research Council criteria (27) ( Table 1) . The large number of variables and case definitions across studies prohibited statistical assessment of heterogeneity and meta-analysis.
RESULTS
Forty-nine abstracts were identified via the electronic and hand-search strategy. Of these abstracts, 31 were ineligible for inclusion because they did not include data about the folatemethionine pathway, data about children with autism was not presented separately from other disorders, and/or because they were not written in the English language. Eighteen studies met the inclusion criteria, of which 17 provided data on metabolites or cofactors of the folate-methionine pathway, 5 provided the results of interventions, and 6 included genetic data.
A summary of studies that measured metabolites and/or cofactors of the folate-methionine pathway is shown in Table 2 . Three studies presented data for multiple metabolites of the folate-methionine and trans-sulfuration pathways (28) (29) (30) . Both studies by James et al (28, 29) showed that, with the exception of SAH and reduced glutathione, specific metabolites of the methionine and trans-sulfuration pathways were significantly decreased. The metabolites measured were methionine, SAM, homocysteine, cysteine, and total glutathione. The authors concluded that the resultant decrease in the SAM:SAH ratio indicates a decreased capacity for methylation in children with autism, and the total glutathione:oxidized glutathione ratio suggests that oxidative stress may play a role in the etiology of autism. In contrast, the study by Suh et al (30) showed no significant change in plasma metabolites of the folate-methionine and trans-sulfuration pathways; lower concentrations of SAM, cysteine, and glutathione; and significantly higher homocysteine concentrations in peripheral leukocytes when children with autism were compared with controls. The discrepancies may have been due to differences in methodology. James et al's studies (28, 29) used HPLC/electrocoulometric detection and the other used liquid chromatography-linked tandem mass spectrometry.
Eleven studies measured plasma concentrations of amino acids associated with the folate-methionine pathway (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . The findings were inconsistent between studies. For example, 3 reported low methionine in plasma of children with autism (28-30), 2 others reported no association (30, 32) , and another reported significantly increased concentrations (31) . Three studies reported low concentrations of cysteine (28, 29, 31) , whereas others reported no significant differences (30, 32) and, although James et al (28, 29) reported a decreased concentration of homocysteine, 2 later studies reported significantly increased concentrations of homocysteine (37, 38) and 2 reported no significant difference (30, 36) .
Ten studies examined cofactors required for folate-methionine metabolism (31, (35) (36) (37) (39) (40) (41) (42) (43) (44) . Of these, 4 studies detected significantly higher serum vitamin B-6 in children with autism than in controls (31, 39, 41, 43) , of which one also found elevated serum concentrations of riboflavin (39) . In addition, a case study reported high vitamin B-12 in a child with autism and CFD (35) ; however, a later study found no significant difference in vitamin B-12 between children with autism and controls (37) . None of the studies found any significant difference in serum or erythrocyte folate between children with autism and controls.
Five studies reported significantly low CSF folate concentrations together with normal serum folate concentrations in children with autism (35, 38, 40, 42, 44) . High titers of FR1 antibodies were found in 19 of 23 children with autism and at least one symptom of CFD (44) .
The findings of the 5 studies that reported the outcome of interventions (28, 35, 38, 42, 44) are presented in Table 3 . A pilot study conducted in a small group of children with autism showed that supplementation with folinic acid and betaine for 3 mo significantly normalized the methionine pathway metabolite profile in plasma, particularly the SAM:SAH ratio (28) . The addition of vitamin B-12 to this regimen for an additional 1 mo in a subset of participants acted mainly on the trans-sulfuration pathway, improving the total glutathione:oxidized glutathione ratio, although it also led to further normalization of methionine metabolites. Quantitative psychometric measures were not, however, included in the study.
The remaining studies reported the effect of treatment with folinic acid on low CSF concentrations of 5-MTHF in children with autism and at least one symptom of CFD (35, 37, 42, 44) . The most autism-specific of these studies showed that treatment with folinic acid resulted in improved autistic, motor, and other neurologic symptoms in young children (,3.5 y) and improvements in motor and neurologic symptoms in older children, although there was no change in autistic symptoms in the older age group (44) .
Six studies examined genes of the folate-methionine pathway or folate transport system in children with autism, which are summarized in Table 4 . The results from these studies were inconsistent. For example, an early study found that the T allele of the MTHFR 677C/T polymorphism was of significantly higher frequency in autistic patients than in controls (P , 0.0001) (45) . The homozygote MTHFR 1298A/C genotype (P = 0.0005) and compound MTHFR 677C/T/1298A/C genotype (P = 0.01) were also significantly associated with the condition. A subsequent larger study, however, failed to confirm (Continued) SAH, S-adenosyl-homocysteine;
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DSM-
III, DSM-III-R, DSM-IV, and DSM-IV-R, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, 3rd edition revised, 4th edition, and 4th edition revised, respectively; CARS, Childhood Autism Rating Scale; 5-MTHF, 5-methyltetrahydrofolate; MTHFR, methylene tetrahydrofolate reductase; OTC, over the counter; CNS, central nervous system; IQ, intelligence quotient; ASD, autism spectrum disorder; LNAA, large neutral amino acids; EEG, electroencephalograph; PDD-NOS, pervasive developmental disorder-not otherwise specified; VABS, Vineland Adaptive Behaviour Scale; ADOS, Autism Diagnostic Observation Schedule; ADI-R, Autism Diagnostic Interview-revised; AMH, Australian Medicines Handbook.
TABLE 3
Studies reporting interventions of the folate-methionine pathway in children with autism Table 1 ). (Continued) FOLATE-METHIONINE PATHWAY AND AUTISM these associations (29) , although a later case report of a child severely affected with autism plus CFD showed that the child was homozygous for the MTHFR 677C/T allele and heterozygous for MTHFR 1298A/C (35). In addition, a borderline association with autism was detected for the 19 base pair (bp) deletion of the dihydrofolate reductase (DHFR) gene [odds ratio (OR): 2.69; 95% CI: 1.00, 7.28; P , 0.05] which is involved in folate metabolism (36) . Significant associations were also found in this study for this polymorphism in combination with MTHFR 677C/T (OR: 2.09; 95% CI: 1.04, 4.18; P , 0.04), MTHFR 677C/T and MTHFR 1298A/C (OR: 1.64; 95% CI: 1.0, 2.69; P , 0.05), and MTHFR 677C/T and RFC-1 80G/A (OR: 1.8; 95% CI: 1.02, 3.18; P = 0.04) (25) . These findings have not been confirmed to date.
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The findings for genes involved in folate transport were also inconsistent. Although the largest study to date found a significant association between RFC-1 80G/A and autism (OR: 2.13; 95% CI: 1.4, 3.4) (29), a subsequent study failed to replicate the findings (37) . On the other hand, an association was found between the 19-bp deletion of DHFR and RFC-1 with autism (36) . Other studies have not found any mutations in genes involved in folate transport (35, 38, 44) .
DISCUSSION
Although the findings of this review indicate inconsistencies between studies, they suggest that the folate-methionine pathway may play a role in the etiology of autism; however, further study is necessary before any definitive conclusions can be made.
Methionine cycle
The largest studies to date that have measured concentrations of the metabolites of the methionine cycle in plasma found that methionine, SAM, and homocysteine were significantly lower and SAH was significantly higher in children with autism than in controls (28, 29) . Although a later study showed no significant differences between children with autism and controls, the number of participants was much lower, which suggests that the findings may be less reliable (30) . The same study identified differences in methionine cycle metabolites from peripheral lymphocytes; however, the presentation of the findings together with the low sample numbers have made interpretation of the data difficult.
Inconsistencies were found between studies in plasma concentrations of all amino acids associated with the methioninetransulfuration pathways. One reason for this may be methodologic differences between studies. For example, homocysteine is released from blood cells into plasma at '10% h at room temperature (46) . Samples, therefore, should be immediately put on ice and the plasma separated out or homocysteine concentrations will be artificially high. The 3 studies that showed higher concentrations of homocysteine in children with autism than in controls do not provide details of how the samples were handled immediately after they were taken (30, 36, 37) . Both publications by James et al (28, 29) , however, indicate that the samples were immediately placed on ice, which lends credence to their findings. 
Case report IV Cases = 1.
See Table 1 .
ADOS, ADI-R. (Continued) In addition, James et al (29) and Adams et al (36) reported borderline associations between some genes of the methionine pathway and autism. The power for both studies, however, was insufficient to provide more than an indication of possible gene associations and neither corrected probability values for chance effects due to multiple comparisons.
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Folate cycle
Folate metabolism is complex. 5-MTHF and vitamin B-12 are required for the conversion of homocysteine into methionine by MS. Low MS activity could lead to an accumulation of 5-MTHF, and intracellular folate retention may be impaired. No significant association between polymorphisms of MS and autism, however, has been shown (36) . Furthermore, various studies have reported vitamin B-12 and erythrocyte folate concentrations are normal in children with autism (31, 36, 39, 40) . Unfortunately, these studies did not identify or control for potential confounders, such as age, neurologic symptoms, or supplementation with cofactors for the folate-methionine pathway. None of the studies reported on plasma concentrations of methylmalonic acid, which is the functional indicator of vitamin B-12 status.
Many biomedical interventions for treating autism have been touted, although most lack an evidence base (47). Whereas James et al (28) showed that supplementation with folinic acid and betaine normalized the plasma concentrations of metabolites in the methionine pathway, and the addition of vitamin B-12 further improved these concentrations, significant autism behavioral outcomes were not measured or observed. On the other hand, supplementation with folinic acid led to improved CFS folate status and remarkable cognitive, motor, and neurologic changes in 15 of 18 children with low-functioning autism and at least one symptom of CFD (44) . This was particularly apparent in younger children, which suggests that damage caused by metabolic dysfunction over time has a degree of irreversibility. The ability to replicate this result by showing an association of neurologic benefits with changes in CSF folate concentration is limited, however, because obtaining CSF folate is a highly invasive procedure.
Vitamin B-6 is required for the conversion of THF to 5,10-MTHF and homocysteine to cysteine via cystathionine. The significant increases in serum vitamin B-6 observed in children with autism (31, 40, 41, 43) could reflect diminished cellular uptake or inefficacy of cells to retain or store vitamin B-6. Impaired bioavailability of vitamin B-6 may affect the nervous system because it is required for the synthesis of neurotransmitters, including serotonin, dopamine, and taurine (48) .
Folate metabolism can also be impaired by 2 polymorphisms of MTHFR, MTHFR 677C/T, and MTHFR 1298A/C, which lower enzyme activity, reduce DNA methylation, and possibly increase chromosomal instability (49) (50) (51) . MTHFR is a pivotal enzyme that catalyses the reduction of 5,10-MTHF into 5-MTHF, which is the major circulating form of folate, and acts as a methyl donor in the remethylation of homocysteine to methionine. Whereas Boris et al (45) reported a significant association for the homozygote MTHFR 677C/T and the compound heterozygote MTHFR 677C/T/1298A/C and autism, other studies did not confirm the association (29, 36) , which may be affected by folate and riboflavin status. The role of this enzyme in autism, therefore, remains unclear; however, again, the studies lacked the power needed to more than indicate a potential association and did not correct for multiple comparisons. Furthermore, Boris et al (45) used genotype data from 2 different sources outside of the study population as controls, which means that cases and controls were not truly matched.
No studies were found that examined the association between MTHFD, an enzyme that catalyses 3 sequential reactions in the interconversion of one-carbon derivatives of tetrahydrofolate, and autism. A borderline association was, however, reported between a 19-bp deletion of DHFR and autism (36) . DHFR maintains the reduced form of folate required for de novo synthesis of methionine and thymine; however, as noted above, this study lacked power and did not correct for multiple comparisons, which made the association tenuous.
James et al (29) reported a significant association between RFC-1 80G/A (OR: 2.13; 95% CI: 1.3, 3.4), and Adams et al (36) reported a borderline association between RFC-1 80G/A and 19-bp del-DHFR (OR: 1.8; 95% CI: 1.02, 3.18) and autism. Their findings suggest that folate transport may be involved in the development of autism; however, as discussed above, both studies lacked power and did not correct for multiple comparisons.
High titers of auto-antibodies to FR1 were reported in children with low-functioning autism and at least one symptom of CFD (44) , although mutations in FR1 or FR2 were not found and mothers did not have the antibody, which led the authors to speculate that it may have been formed from milk protein (38, 44) . The plausibility of an association of FR1 auto-antibodies with neural deficits is supported by the observations of antibodies against placental FR proteins being associated with neural tube defects (52) .
Conclusions
A better understanding of the metabolic basis of autism has the potential to guide the development of a laboratory-based "test" to diagnose autism, predict the outcome of disease, and assign the most appropriate intervention. Although the findings of this review do not conclusively implicate a dysfunctional folate-methionine pathway in the etiology of autism, the topic clearly deserves scrutiny. Any review of evidence will be confounded by the heterogeneity of autism, sampling issues, and the wide range of analytic techniques used. Given the increase in community awareness of autism in recent years and the consequent increased focus on autism research, the findings of the more recently published studies are likely to be more reliable, although they are still inconsistent. These findings suggest that changes in the concentrations of metabolites of the methionine cycle may be driven by abnormalities in folate transport and/or metabolism. Almost all of the genetic association studies that have examined the genes of this metabolic pathway were under powered. As autism is a complex genetic disease, the relative risk conferred by each disease-associated allele is likely to be small; therefore, large patient and control groups are required for statistical significance. Furthermore, many of the studies examined multiple polymorphisms and their interactions without correcting for multiple comparisons may have been better analyzed by using logistic regression analysis.
Whereas supplementation can normalize the concentrations of the folate-methionine metabolites, whether or not normalization affects objective behavioral measures needs to be determined to assess the clinical relevance. Supplementation has been shown to be most effective in improving autistic behavior, motor, and neurologic symptoms in younger children (aged ,3 y) with lowfunctioning autism and CFD (44) ; however, it remains to be seen whether this holds for children with autistic disorder without CFD. Large-scale studies that link normalization of metabolite concentrations with genetic polymorphisms and objective behavioral measures are needed to address these issues. In addition, a large-scale retrospective survey should be conducted in mothers of children with and without autism to ascertain the association level of folate supplementation before and during pregnancy with the risk of having a child with autism and whether susceptibility genes in the folate-methionine pathway modify such a risk if present. Overall, this review concluded that evidence suggests a role for the folate-methionine pathway in autism and suggests some future directions for research.
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